CoChat
Sign Up
Cited by 120

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Hepatic Proprotein Convertases Modulate HDL Metabolism

Jin, Weijun, Wang, Xun, Millar, John S., Quertermous, Thomas, Rothblat, George H., Glick, Jane M., Rader, Daniel J.·2007·Cell Metabolism
DOI 10.1016/j.cmet.2007.07.009
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2007.07.009

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ANGPTL3 contains a protease cleavage site and in vivo can be cleaved into two domains both intracellularly by PCSK3 and extracellularly by PACE4.

    “ANGPTL3 contains a protease cleavage site, and in vivo can be cleaved into two domains both intracellularly by PCSK3 and extracellularly by PACE4 (107, 124, 131, 132).”

    From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [124]

  • The N-terminal cleavage product of ANGPTL3 is necessary and sufficient for lipase inhibition.

    “Several studies have identified the N-terminal cleavage product to be necessary and sufficient for lipase inhibition (107, 123, 124).”

    From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [124]

  • In vitro studies of the effect of cleavage on ANGPTL3-mediated inhibition have reported increased inhibition, decreased inhibition, and no effect on inhibition.

    “In vitro studies of the effect of cleavage on ANGPTL3-mediated inhibition have reported increased inhibition, decreased inhibition, and no effect on inhibition (107, 115, 124).”

    From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [124]

  • ANGPTL3 is a known inhibitor of endothelial lipase.

    “ANGPTL3 is a known inhibitor of endothelial lipase (123, 124).”

    From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [124]

  • Subsequent studies confirmed the ability of ANGPTL3 to inhibit EL.

    “Subsequent studies confirmed the ability of ANGPTL3 to inhibit EL (124).”

    From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [124]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet., 34, 154, 10.1038/ng1161 · DOI · Paper page
  2. Acton, 1996, Identification of scavenger receptor SR-BI as a high density lipoprotein receptor, Science, 271, 518, 10.1126/science.271.5248.518 · DOI · Paper page
  3. Basak, 2005, Inhibitors of proprotein convertases, J. Mol. Med., 83, 844, 10.1007/s00109-005-0710-0 · DOI
  4. Benjannet, 2001, Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production, J. Biol. Chem., 276, 10879, 10.1074/jbc.M009899200 · DOI · Paper page
  5. Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol, J. Biol. Chem., 279, 48865, 10.1074/jbc.M409699200 · DOI · Paper page
  6. Bojanovski, 1987, In vivo metabolism of proapolipoprotein A-I in Tangier disease, J. Clin. Invest., 80, 1742, 10.1172/JCI113266 · DOI
  7. Christiansen-Weber, 2000, Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis as well as high-density lipoprotein cholesterol deficiency, Am. J. Pathol., 157, 1017, 10.1016/S0002-9440(10)64614-7 · DOI
  8. Goldstein, 2002, Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis, Arch. Biochem. Biophys., 397, 139, 10.1006/abbi.2001.2615 · DOI · Paper page
  9. Ishida, 2003, Endothelial lipase is a major determinant of HDL level, J. Clin. Invest., 111, 347, 10.1172/JCI16306 · DOI
  10. Jaye, 1999, A novel endothelial-derived lipase that modulates HDL metabolism, Nat. Genet., 21, 424, 10.1038/7766 · DOI · Paper page
  11. Jin, 2003, Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo, J. Clin. Invest., 111, 357, 10.1172/JCI16146 · DOI
  12. Jin, 2005, Proprotein convertases [corrected] are responsible for proteolysis and inactivation of endothelial lipase, J. Biol. Chem., 280, 36551, 10.1074/jbc.M502264200 · DOI · Paper page
  13. Koishi, 2002, Angptl3 regulates lipid metabolism in mice, Nat. Genet., 30, 151, 10.1038/ng814 · DOI · Paper page
  14. Ma, 2003, Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism, Proc. Natl. Acad. Sci. USA, 100, 2748, 10.1073/pnas.0438039100 · DOI · Paper page
  15. Maxwell, 2004, Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype, Proc. Natl. Acad. Sci. USA, 101, 7100, 10.1073/pnas.0402133101 · DOI · Paper page
  16. Nour, 2003, Structure-function analysis of the prosegment of the proprotein convertase PC5A, J. Biol. Chem., 278, 2886, 10.1074/jbc.M208009200 · DOI
  17. Ono, 2003, Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo, J. Biol. Chem., 278, 41804, 10.1074/jbc.M302861200 · DOI · Paper page
  18. Park, 2004, Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver, J. Biol. Chem., 279, 50630, 10.1074/jbc.M410077200 · DOI · Paper page
  19. Rader, 2006, Molecular regulation of HDL metabolism and function: implications for novel therapies, J. Clin. Invest., 116, 3090, 10.1172/JCI30163 · DOI
  20. Roebroek, 2004, Limited redundancy of the proprotein convertase furin in mouse liver, J. Biol. Chem., 279, 53442, 10.1074/jbc.M407152200 · DOI
  21. Scamuffa, 2006, Proprotein convertases: lessons from knockouts, FASEB J., 20, 1954, 10.1096/fj.05-5491rev · DOI
  22. Seidah, 1999, Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides, Brain Res., 848, 45, 10.1016/S0006-8993(99)01909-5 · DOI
  23. Sewell, 2006, Proteomic signatures in laryngeal squamous cell carcinoma, ORL J. Otorhinolaryngol. Relat. Spec., 69, 77, 10.1159/000097406 · DOI
  24. Shimamura, 2007, Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase, Arterioscler. Thromb. Vasc. Biol., 27, 366, 10.1161/01.ATV.0000252827.51626.89 · DOI · Paper page
  25. Shimizugawa, 2002, ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase, J. Biol. Chem., 277, 33742, 10.1074/jbc.M203215200 · DOI · Paper page
  26. Watanabe, 1995, Engineered serine protease inhibitor prevents furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus, J. Virol., 69, 3206, 10.1128/JVI.69.5.3206-3210.1995 · DOI
  27. Yancey, 2004, SR-BI- and ABCA1-mediated cholesterol efflux to serum from patients with Alagille syndrome, J. Lipid Res., 45, 1724, 10.1194/jlr.M400133-JLR200 · DOI
  28. Zhang, 2003, Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo, Circulation, 108, 661, 10.1161/01.CIR.0000086981.09834.E0 · DOI
  29. Zhong, 1999, The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In vitro and ex vivo assessment of their efficacy and selectivity, J. Biol. Chem., 274, 33913, 10.1074/jbc.274.48.33913 · DOI

Cited by

Sorted by citations

Metadata

Authors
Jin, W., Wang, X., Millar, J. S., Quertermous, T., Rothblat, G. H., Glick, J. M., & Rader, D. J.
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2007-08
Volume
6
Issue
2
Pages
129-136
ISSN
1550-4131
DOI
10.1016/j.cmet.2007.07.009
Cited by
120
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review